Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 5.6% – Here’s Why

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were down 5.6% during mid-day trading on Tuesday . The company traded as low as $3.18 and last traded at $3.1330. Approximately 174,614 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 2,572,239 shares. The stock had previously closed at $3.32.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Wells Fargo & Company boosted their price target on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 11th. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Weiss Ratings restated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, November 17th. Finally, Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Ironwood Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $5.34.

Ironwood Pharmaceuticals Trading Down 4.1%

The company has a 50-day moving average of $1.90 and a 200-day moving average of $1.21. The company has a market capitalization of $517.97 million, a price-to-earnings ratio of -63.49 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Monday, November 10th. The biotechnology company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.15. The firm had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Inspire Investing LLC increased its stake in Ironwood Pharmaceuticals by 138.3% during the second quarter. Inspire Investing LLC now owns 552,420 shares of the biotechnology company’s stock worth $396,000 after acquiring an additional 320,595 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Ironwood Pharmaceuticals by 160.7% in the first quarter. Acadian Asset Management LLC now owns 2,645,189 shares of the biotechnology company’s stock worth $3,878,000 after acquiring an additional 1,630,726 shares in the last quarter. Voleon Capital Management LP raised its position in Ironwood Pharmaceuticals by 952.4% in the 1st quarter. Voleon Capital Management LP now owns 870,629 shares of the biotechnology company’s stock valued at $1,280,000 after purchasing an additional 787,901 shares in the last quarter. Los Angeles Capital Management LLC lifted its stake in Ironwood Pharmaceuticals by 76.1% in the second quarter. Los Angeles Capital Management LLC now owns 1,211,155 shares of the biotechnology company’s stock worth $869,000 after acquiring an additional 523,368 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC grew its stake in shares of Ironwood Pharmaceuticals by 284.6% during the second quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 29,409 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.